Mei Pharma Inc Stock Price, News & Analysis

MEI Pharma, Inc. (NASDAQ: MEIP) announced the retirement of CFO Brian Drazba, effective end of 2021, after serving since April 2017. Drazba has been pivotal in enhancing the company's financial infrastructure and will support the transitional phase. MEI Pharma is actively searching for a new CFO. The company specializes in developing cancer therapies, with a pipeline that includes four clinical-stage drug candidates, such as zandelisib, currently undergoing multiple trials to gain regulatory approvals.

MEI Pharma, Inc. (NASDAQ: MEIP) has announced the granting of inducement stock options for 306,000 shares to seven new employees, aimed to attract talent. The options, priced at $2.70, match the stock's closing price on the grant date and are part of MEI's 2021 Inducement Grant Equity Compensation Plan. They will vest over a period of time with a term of 10 years. This move aligns with Nasdaq Listing Rule 5635(c)(4), requiring prompt disclosure via press release. The company continues to focus on developing new cancer therapies, with zandelisib undergoing a Phase 2 clinical trial.

MEI Pharma (NASDAQ: MEIP) has appointed Tina C. Beamon, J.D., as chief compliance officer to oversee compliance programs. Beamon brings over 20 years of experience from the healthcare and pharmaceutical sectors, having previously held leadership roles at Karyopharm Therapeutics and Alexion Pharmaceuticals. Her expertise is expected to strengthen MEI's compliance as the company prepares for the commercialization of its lead drug candidate, zandelisib, currently in Phase 2 trials.

MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of inducement stock options for 169,000 shares to three new employees. The options have an exercise price of $2.85, equal to the stock's closing price on the grant date. Approved by the Compensation Committee, these options vest gradually over ten years. MEI Pharma focuses on developing cancer therapies, with clinical-stage assets like zandelisib. The press release notes potential risks associated with FDA approvals and market acceptance, highlighting the uncertainties of drug development.

MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin announced clinical data from a Phase 1b study evaluating zandelisib, a selective PI3K delta inhibitor for treating B-cell malignancies. The data will be showcased at the 16th International Conference on Malignant Lymphoma from June 18-22, 2021. The study aims to address patients with follicular lymphoma who progressed within 24 months of first-line therapy. Additionally, the Phase 3 COASTAL study will investigate zandelisib combined with rituximab versus conventional therapies for relapsed or refractory indolent non-Hodgkin's lymphoma.

MEI Pharma and Kyowa Kirin have initiated the second arm of the global Phase 2 TIDAL study, dosing the first patient with relapsed or refractory marginal zone lymphoma. This arm evaluates zandelisib, a PI3K delta inhibitor, alongside a previous arm focusing on follicular lymphoma. Both arms aim for separate FDA accelerated approval applications. The study will assess objective response rates and tolerability of zandelisib. This collaboration between the companies highlights their commitment to advancing therapeutic options for patients with B-cell malignancies.

MEI Pharma, Inc. (NASDAQ: MEIP) will host a video webcast for investors and analysts on June 10, 2021, at 12:00 PM ET, following the 2021 ASCO Annual Meeting. The event will cover updates on the zandelisib program, including data presented at ASCO, with insights from Dr. Deepa Jagadeesh of the Cleveland Clinic. The webcast can be accessed on MEI's investor relations website, and a replay will be available for 30 days. MEI focuses on developing innovative cancer therapies and has four clinical-stage assets, including zandelisib, which is in a Phase 2 trial.

On May 19, 2021, MEI Pharma announced promising data for zandelisib, a PI3Kδ inhibitor, aimed at treating B-cell malignancies. Key findings include an 87% overall response rate in relapsed or refractory follicular lymphoma patients, with 93% in non-POD24 patients. The Phase 3 COASTAL study, comparing zandelisib plus rituximab to standard chemotherapy in indolent non-Hodgkin's lymphoma, is set to enroll 534 patients. Topline results from the ongoing Phase 2 TIDAL study are expected later this year, reinforcing the commitment to zandelisib's development as a potential best-in-class therapy.

MEI Pharma and Kyowa Kirin have announced updated clinical data from a Phase 1b study of zandelisib, a selective PI3Kδ inhibitor, in combination with zanubrutinib, for patients with relapsed or refractory B-cell malignancies. This data will be presented at the European Hematology Association (EHA) 2021 Virtual Congress from June 9-17, 2021. The study aims to assess the drug combination's tolerability and efficacy, potentially leading to improved therapeutic options for patients. The abstract is accessible on the EHA website.